Integrity Alliance LLC. Purchases Shares of 4,522 Celcuity, Inc. $CELC

Integrity Alliance LLC. purchased a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) during the fourth quarter, Holdings Channel.com reports. The firm purchased 4,522 shares of the company’s stock, valued at approximately $451,000.

A number of other hedge funds have also bought and sold shares of the stock. Jefferies Financial Group Inc. acquired a new position in Celcuity during the 4th quarter valued at approximately $703,000. EverSource Wealth Advisors LLC increased its stake in Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after purchasing an additional 319 shares in the last quarter. PSP Research LLC acquired a new position in Celcuity during the 4th quarter valued at approximately $523,000. Atle Fund Management AB increased its stake in Celcuity by 12.6% during the 4th quarter. Atle Fund Management AB now owns 41,831 shares of the company’s stock valued at $4,172,000 after purchasing an additional 4,674 shares in the last quarter. Finally, Profund Advisors LLC acquired a new position in Celcuity during the 4th quarter valued at approximately $2,116,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Stock Up 1.5%

CELC stock opened at $132.88 on Friday. The firm has a market cap of $6.48 billion, a PE ratio of -34.07 and a beta of 0.09. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. The firm’s fifty day moving average is $123.09 and its 200 day moving average is $110.94. Celcuity, Inc. has a one year low of $10.50 and a one year high of $151.02.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.10. On average, research analysts forecast that Celcuity, Inc. will post -3.96 EPS for the current year.

Wall Street Analyst Weigh In

CELC has been the topic of a number of research reports. Wall Street Zen lowered shares of Celcuity from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Wells Fargo & Company increased their price objective on shares of Celcuity from $150.00 to $183.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. Wolfe Research reiterated an “outperform” rating and issued a $110.00 price objective on shares of Celcuity in a research note on Thursday, March 12th. HC Wainwright increased their price objective on shares of Celcuity from $165.00 to $185.00 and gave the stock a “buy” rating in a research note on Monday, May 18th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $157.00 price objective on shares of Celcuity in a research note on Friday, May 15th. Eleven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $150.27.

Insider Buying and Selling at Celcuity

In related news, Director David Dalvey sold 25,000 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the sale, the director owned 65,000 shares in the company, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the sale, the director owned 6,760 shares in the company, valued at approximately $949,509.60. This represents a 57.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 37,000 shares of company stock worth $5,111,950. 13.33% of the stock is owned by company insiders.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.